Brian Yang
Verified
As seen in:
STAT,
LinkedIn,
Wiley Online Library,
Substack,
Taylor & Francis Online,
Flipboard,
Patch,
The Boston Globe,
beehiiv,
EIN News,
Lexology
and
contributing writer @statnews cover China biotech for over a decade
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Brian Yang
The Death of an Economist: How Gao Shanwen’s 18-month Ordeal Exposes China Cell Therapy’s Overlooked Gap
Capition: Gao Shanwen died at 55, after 18-month battle with lymphoma. AI-generated Gao, a well-known macroeconomist’s passing, after a short one year and a half battle with a rare cancer, sparks wide debate about cell therapy development and clinical use in China, the country with the largest cell therapy development pipeline in the world. Gao’s illness unfolded over nearly eighteen months, crossing multiple hospitals in Beijing, Hong Kong, and finally back to Beijing.
After 20 Years Covering Biotech, Why I Wrote About Chinese and Chinese American Scientists
When Xiuli Wang stood at a podium at Peking University one day in 2018, she was full of hope for a promising therapy, CAR-T cell therapy to treat one of the most fatal blood cancers, lymphoma. Wang was a research professor and director of hematology and hematopoietic cell transplantation at City of Hope, in Los Angeles.
The U.S.-China biotech crackdown may hurt the scientists America needs the most
By Brian Yang June 29, 2026 Yang is New York-based journalist. He spent more than 12 years covering the biotech sector from Beijing as managing editor of Citeline’s Scrip and Pink Sheet. I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years.
The Rise and Fall of "China’s Moderna"
Founder of a collapsed biotech once raised billions of RMB in funding shares his insider views on China mRNA vaccine development. One day in September 2023, Hangwen Li received a white envelope containing a devastating court order: “The court has placed a restriction order on your spending on any unnecessary expenses…” The founder of a company once valued at billions was suddenly barred from buying airline tickets, booking train business seats, or purchasing a vehicle.
Brian Yang to Appear on Love Experts TV
FL, UNITED STATES, June 5, 2026 / EINPresswire.com/ -- Brian Yang, founder of Awakening With Brian and a somatic healing practitioner focused on breaking generational relationship patterns, is set to appear on Love Experts TV, where he will share insights on somatic-based approaches to recurring relational dynamics and emotional healing. Love Experts is a television series exploring the science, psychology, and real-world experience behind modern relationships.
Can China Make Gene Therapy Affordable? Lingyi Bio Best on Wilson’s Disease
For years, Yiwei Chen thought she simply lacked physical strength. Her mother thought otherwise – calcium deficiency. Only after completing medical school did she discover the right diagnosis, explaining why she needed a wheelchair to commute: Wilson’s disease, a rare inherited disorder that causes toxic copper accumulation in the body. Now a popular science educator, Chen’s long journey to get a clear and accurate diagnosis is shared by many.
Hengrui’s Significant Other: Hansoh Pharma and its Oncology Global Buildout
Hengrui Medicines CEO Piaoyang Sun and Hansoh Pharma CEO Huijuan Zhong are a couple. In the shadow of the most innovative Chinese domestic drug maker, Hansoh, however shines with its own strings of deals. The Lianyungang, Jiangsu-based company have nurtured deals with global pharma companies from Roche, GSK, and Merck. Less known to the outside world, Hanshoh is quietly building one of China's most ambitious oncology pipelines.
Five myths people often have about China
Wearing my cross-cultural communicator hat, I demystify five myths people often have about China: 1. “You don’t need to go to China to understand China.” Actually, you do. No book, documentary, or podcast fully captures the experience of standing on a Beijing street corner and noticing surveillance cameras mounted almost everywhere — on light poles, storefronts, building entrances, intersections.
Can AI solve What Wellness Programs Fail: Behavior Change, at Scale?
An insurance company analyzed 47 million sleep data points — and found a 22% reduction in mortality from consistent 7–9 hours of sleep. That's not a wellness tip. That's a business case. Discovery, the South African insurer behind the Vitality program, presented new findings at Columbia University's AI Longevity series this week. The thesis is simple: healthier people cost less. The execution is anything but.
How a Chinese biotech Reinvented Its Rare Disease Business
In China’s brutal biotech downturn, few companies have staged a comeback as dramatic as CANbridge Pharma. After its shares collapsed and capital dried up, the rare disease drugmaker cut most of its staff, outsourced commercialization, and rebuilt its business model from the ground up. By late 2023, CANbridge’s shares had collapsed alongside much of China’s biotech sector, falling from around HK$2 to nearly HK$0.15 at their lowest point.
Delaware Supreme Court Rejects Bright Line Rules in Section 220 Books and Records Proceedings
delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
Posts from: Brian Lutz
Delaware Supreme Court Rejects Bright Line Rules in Section 220 Books and Records Proceedings delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
Posts from: Monica Loseman
Delaware Supreme Court Rejects Bright Line Rules in Section 220 Books and Records Proceedings delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
Posts from: Michael Kahn
Delaware Supreme Court Rejects Bright Line Rules in Section 220 Books and Records Proceedings delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
Posts from: Jason Mendro
Delaware Supreme Court Rejects Bright Line Rules in Section 220 Books and Records Proceedings delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
The Harvard Law School Forum on Corporate Governance
delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
China Wants Innovative Drugs to Stay Domestic, Longer. Global Pharma Should Take Notice
For the past five years, China’s public payer, the National Healthcare Insurance Administration, has aggressively slashed drug prices by 50% as a starting point to cover newly approved drugs. That has been one major factor driving many Chinese biotech companies to go abroad to license their innovative assets to Western companies to fund their domestic R&D expenses.
China Biotech Self-Reliance Push Could Close off a Key Pipeline for Global Pharma
The U.S. export control is reshaping China’s access to advanced chips, and companies like Alibaba and Huawei are accelerating efforts to build domestic alternatives, signaling a broader shift toward technological self-reliance. What’s unfolding in China’s semiconductor sector may offer an early warning for biotech: as policy, capital, and talent align around self-reliance, foreign access to China’s innovation pipeline could narrow—just as that pipeline becomes more globally competitive.
Hematology CRO Services | Parexel
Parexel is a global leader in lymphoma with significant experience in B-cell, T-cell, follicular, Hodgkin’s, non-Hodgkin’s, and mantle cell lymphoma. We maintain strong relationships with patient advocacy groups specific to this therapeutic area. Our team conducted the first-ever comparator cohort study by a company seeking approval in the U.S. and EU for a lead product in oncology rare disease in lymphoma.
China’s 996 Culture Has a Health Consequence We’re Ignoring
A 41-year-old founder died at work. The real problem isn't what you think On March 24, Xuefeng Zhang—known to millions of Chinese students as “Teacher Zhang”—collapsed on a treadmill in his Suzhou office during a lunch break. Two hours later, he was dead. He was 41. For years, Zhang had been a guiding voice for a generation navigating an unforgiving job market.
Why a Beloved Teacher’s Sudden Death Exposes a Critical Gap in China’s Healthcare System
On March 24, Xuefeng Zhang—known to millions of Chinese students as “Teacher Zhang”—collapsed on a treadmill in his Suzhou office during a lunch break. Two hours later, he was dead. He was 41. For years, Zhang had quietly cultivated as a guiding voice for a generation navigating an unforgiving job market.
Biotech VCs move upstream in China’s scientific pipelines as competition grows fiercer
4 hours ago Korean Air says it is moving into emergency management mode to buffer the impact of surging jet fuel costs as the global economy is rocked by the ongoing US-Israel war with Iran. A spokesperson for the national flag carrier said on Tuesday that it will implement "internal cost-reduction measures" to …
The Country With a 16% Obesity Rate That Sounds More Alarmed Than America
With only 16% of its population classified as obese, China is among the leaner nations in the world. Yet the National Health Commission just declared 2026 the National Weight Loss Year. The gap between the statistics and the urgency reveals a lot — about how Chinese bodies store fat, how the government manages healthcare costs, and a youth obesity trend that is quietly accelerating.
U.S. Biotech Grapples with China’s Speed—and Its Consequences
As China accelerates drug development and forging licensing deals at a speed few expected, U.S. biotech leaders are increasingly divided over what it means: a global opportunity to collaborate—or a structural challenge to American leadership. At STAT Breakthrough East, a conference held on March 19, executives from Biogen and Bristol Myers Squibb, alongside academic leaders, framed China’s rise less as a direct threat and more as a force reshaping how innovation happens across borders.
Everyone deserves better health care
Over the past decade, Canada has witnessed a marked decline in access to primary care, a foundational element of its publicly funded health system.
Why China Could See Major Setbacks as the U.S. Expands Combat in Iran
U.S. military strikes on Iran risk derailing one of China’s quieter—but strategically important—projects in the Middle East: health diplomacy. From patient monitors to cancer drugs, from AI to vaccines, China as the major supplier of medical devices and health products to Iran, could see some major impact from the Washington's War in Iran. As U.S. President Trump launched a major combat operation against Tehran, global attention once again turned to China’s expanding footprint in the region.
Why Lilly Mega Deal could signal China’s Next ADC-assets
Plus: Madrgal and Ribo Bio, Innovent Bio and Lilly Two back-to-back deals this week caught my attention. On Feb. 9, Eli Lilly& Co agreed to purchase Boston area-based biotech Orna Therapeutics for $2.4 billion in cash. The mega, multi-billion-dollar deal is centered on one thing: circular RNA. Orna is developing innovative medicines using circular RNA as a novel technology that can manipulate a patient’s genes or and cells to fight medical conditions.
Why Hong Kong Has Become the Go-To IPO Destination for China Biotech
Just last week (Jan. 18-23), three innovative drug developers filed for Hong Kong listings—signaling the sustained momentum in China's biotech capital markets. The Latest Wave: Prime Gene – The Beijing-based biotech is a developer of small-molecule ointment drugs for inflammatory conditions.
Robot wars: The battle for robotic surgery at community hospitals across Canada
License You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association.
Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis
ABSTRACT Background With the increasing use of medical cannabis (MC), there is growing evidence suggesting that MC may be an effective therapeutic for chronic sleep, pain, and anxiety conditions. However, further evaluation is warranted to evaluate the heterogeneous patient outcomes of authorized cannabis treatment. Aims To assess the effectiveness of authorized cannabis on pain, sleep duration, anxiety, and depression in patients presenting to clinics over a 6-month time period.
Currency Appreciation, Cell Therapy Deep Discount: What’s Shifting in China Biotech
At Davos, Chinese Vice Premier He Lifeng pushed back against protectionism, pitching China as a “partner, not a rival.” Chinese currency, meanwhile, is strengthening. A stronger yuan could attract foreign investors to return, especially in the biopharma sector, says one fund manager. Huadao Biotech has filed a CAR-T therapy for non-Hodgkin lymphoma with China’s drug regulator. The headline number is striking: RMB 230,000–250,000 per treatment. #CGT #Chinabiotech #healthinnovation
Currency Appreciation, Cell Therapy Deep Discount: What’s Shifting in China Biotech
Have you noticed something subtle changing? I’m not talking about Greenland or Iran — but something that could have equally far-reaching consequences for global healthcare and capital flows: a strengthening Chinese currency and a potential re-opening of foreign investment into China’s health sector. The renminbi has appreciated 0.72% over the past month and 4.4% year-on-year, briefly dipping below 7 to the U.S. dollar in January — a key psychological threshold.
China Looms Large at JPM26 Again. Key Players Skip San Francisco
From packed corridors to gene therapy seminars, China dominated conversations at this year's JPMorgan Healthcare Conference. Yet many Chinese biotechs—including those fresh off major licensing deals—were conspicuously absent from the gathering. Tony Xue, founder of Suzhou-based Medlink Therapeutics, told me he skipped the conference despite his company's recent momentum.
China Biotech Threat Talk: To Be Continued at JPM26?
Biotech's Biggest Buzz: Here I Come The signals are mixed. One Chinese biotech founder has already told me he's not coming. Whether JPM 2026 marks another breakthrough year for China biotech or a retreat from last year's record-breaking dealmaking, the mood remains enthusiastic—but uncertain. The question hanging over this year's conference: Can China biotech match 2025's historic momentum, or are we entering a more cautious phase?
Is China Arriving, or Has China Already Arrived?
If CES is the kickoff show for the electronics sector, JPM Global Healthcare Conference is the one for biotech. And the numbers from both tell a compelling story. At CES 2026, to be concluded this Friday, at least 900 Chinese tech companies exhibited—representing one quarter of all exhibitors in Las Vegas.
Taming the Immaturity of Neutrophils Driving Injury in Lung Transplantation
Get full text access Log in, subscribe or purchase for full access. References 1. Cantu, E. ∙ Diamond, J.M. ∙ Cevasco, M. ... Contemporary trends in PGD incidence, outcomes, and therapies J Heart Lung Transpl. 2022; 41:1839-1849 Published online August 31 2. Gelman, A.E. ∙ Fisher, A.J. ∙ Huang, H.J. ...
Taming the Immaturity of Neutrophils Driving Injury in Lung Transplantation
Keywords neutrophils lung transplant primary graft dysfunction chronic lung allograft dysfunction CD10 Get full text access Log in, subscribe or purchase for full access. References 1. Cantu, E. ∙ Diamond, J.M. ∙ Cevasco, M. ... Contemporary trends in PGD incidence, outcomes, and therapies Published online August 31 J Heart Lung Transplant. 2022; 2. Gelman, A.E. ∙ Fisher, A.J. ∙ Huang, H.J. ...
PanGen Biotech, Inc.
|
Privacy Preference Center When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.
By Anju Ghangurde Verified, Joseph Haas Verified, Ian Haydock Verified, Lisa Takagi Verified, Dexter Yan Verified, Brian Yang Verified
|
Citeline
Verified
Orphalan
According to the latest National New Drug Approval Report for 2023 from China's National Medical Products Administration (NMPA), 15 orphan drugs were approved through the regulator's designated priori
Vigonvita Life Sciences Co., Ltd
Privacy Preference Center When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.
The Harvard Law School Forum on Corporate Governance
Delaware Supreme Court Rejects Bright Line Rules in Section 220 Books and Records Proceedings delaware, DGCL Section 220, Paramount, post-demand evidence, stockholders More from: Brian Lutz, Brian Yang, Craig Varnen, Jason Mendro, Michael Kahn, Monica Loseman , Gibson Dunn Michael J. Kahn is a Partner and Brian Yang is an Associate Attorney at Gibson, Dunn & Crutcher LLP. This post is based on a Gibson Dunn memorandum by Mr. Kahn, Mr. Yang, Monica K. Loseman, Brian M. Lutz, Jason J.
China Biotech’s “Mamdani Moment”
LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy. Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.
Why Fentanyl May Decide the Success of the Trump-Xi Meeting
As President Donald Trump and Chinese President Xi Jinping prepare to meet in South Korea, a 20% “fentanyl tariff” has emerged as one of the most contentious issues on the table. Beijing is eager to reduce the additional duties, levied on many Chinese goods since this February. Daojiong Zha, a professor of international political economy at Peking University’s School of International Studies, shared his views on fentanyl ahead of the summit.
Chinese biotech industry shows no signs of slowing as threat of U.S. restrictions loom
China: Gymgoer drops dumbbell on his smartphone causing it to explode in smoke Guangdong Province, China - October 21, 2025 This is the shocking moment a gym-goer accidentally dropped a dumbbell on his smartphone, causing it to burst into smoke. CCTV footage shows the fitness enthusiast lying on a bench while lifting weights in Guangdong, China. Moments later, he lowered the equipment and dropped it onto the floor, hitting his phone that had been placed nearby on October 21.
Inveresk Research Group Inc.
Industry Biotechnology Drug Discovery Technologies Pharmacogenetics-Pharmacogenomics Pharmaceuticals Contract Research Organization-CRO Scrip Asia On The Move: CFDA Deputy Commissioner Moves To Sichuan Apr 06 2015 • By Asia On The Move is a regular column highlighting industry personnel changes in Asia-Pacific. The last column covered new reviewers at China’s Center for Drug Evaluation ( [A#28150211006] ).
Nobel Prize, Immune Modulating Mechanism and Future Applications
In 2005, when Japan increased its research funding, it set a goal of achieving 30 Nobel laureates over the following 50 years, a target many considered ambitious. Yet by 2025, Japan has not only stayed on track but exceeded expectations — with 29 Nobel laurates to date and 13 since 2005. Most recently, Kyoto University professor Shimon Sakaguchi won the 2025 Nobel Prize in Physiology or Medicine, alongside American immunologists Mary E. Brunkow and Fred Ramsdell.
Special Edition: What a Weeklong Trip Reveals about U.S.-China Biotech Competition
Happy Monday! Atter spending the past week in China, from biotech hub Shanghai to other cities, I have the following dispatches. Shanghai is buzzing, yet the excitement is focused on breakthrough science and local rivalry—not global deal-making. Relocated to a larger ballroom near Hongqiao after overwhelming demand, the event overflowed with young talent in their 30s and 40s.
Aim for BeiGene? You Need Professional Managers: New Episode on Biotech Leadership, Incentives, and Retention
Brian Yang Brian Yang Published Sep 26, 2025 The Dilemma China’s biotech boom exposed a major Achilles’ heel: most early-stage firms are led by scientist-founders. While this ensures a strong R&D base, scaling up requires operational and commercial skills beyond pure science. Why the Shift Matters Scaling needs expertise: Moving from discovery to trials and commercialization isn’t just academic—it’s operational.
What Behinds Chinese Insurers Piling into A Shares as Economic Downturn Deepens
For the first time ever, all five major Chinese insurers—Ping An, China Life, New China Insurance (NCI), China Pacific Insurance (CPCI), and People’s Insurance—have poured record funds into the A-share stock market, driving a historic surge. Today’s Big Picture: Insurance “National Team” in Action Historic Flows: Over RMB 1.1 trillion ($150B+) in insurer assets went into equities during H1 2025, according to Wallstreetcn.
What to Know about J&J $67 million Investment in Chinese Robotic Surgical Startup
On September 12th, Johnson &Johnson made a minority equity investment in Renovo Surgical, a Shanghai-based startup founded in 2019 by John Ma (ex-Intuitive Surgical) and Ying Mao (ex-Auris Health) executives. Renovo has already obtained a Chinese approval for its surgery robotics Carina and J&J is filing a FDA approval application for its Ottava, both tackle soft tissue procedures. Is J&J investing in a competitor in China and even globally?
Show More
loading
Actions
Get in touch with Brian
Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack